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ABSTRACT
Chest computed tomography (CT) is widely used for the management of Coronavirus disease 2019 (COVID-19) pneumonia
because of its availability and rapidity1–3 . The standard of reference for confirming COVID-19 relies on microbiological tests
but these tests might not be available in an emergency setting and their results are not immediately available, contrary to CT. In
addition to its role for early diagnosis, CT has a prognostic role by allowing visually evaluating the extent of COVID-19 lung
abnormalities4,5. The objective of this study is to address prediction of short-term outcomes, especially need for mechanical
ventilation. In this multi-centric study, we propose an end-to-end artificial intelligence solution for automatic quantification and
prognosis assessment by combining automatic CT delineation of lung disease meeting expert’s performance and data-driven
identification of biomarkers for its prognosis. AI-driven combination of variables with CT-based biomarkers offers perspectives
for optimal patient management given the shortage of intensive care beds and ventilators6,7.
Main
COVID-19 has emerged in December 2019 in the city of Wuhan in China8 and disseminated around the world, leading the
World Health Organization to declare the COVID-19 outbreak a pandemic. The disease is caused by the SARS-Cov-2 virus
and the leading cause of death is respiratory failure due to severe viral pneumonia9. Chest computed tomography (CT) has
rapidly gained a major role for COVID-19 diagnosis. Indeed, despite being considered as the gold standard to make a definitive
diagnosis, reverse transcription polymerase chain reaction (RT-PCR) suffers from false negatives, shortage of available supply
test kits and long turnaround times10–12.
Artificial intelligence has gained significant attention during the past decade and many applications have been proposed in
medical imaging, including segmentation and characterization tasks such as lung cancer screening on CT13–15. A few studies
have already reported deep learning to diagnose COVID-19 pneumonia on chest radiograph16 or CT17 . Other authors used
Figure 1. Overview of the method for CT-based quantification, staging and prognosis of COVID-19. (i) Two independent
cohorts with quantification based on ensemble 2D & 3D consensus neural networks reaching expert-level annotations on
massive evaluation, (ii) Consensus-driven bio(imaging)-marker selection on the principle of prevalence across methods leading
to variables highly-correlated with outcomes & (iii) Consensus of linear & non-linear classification methods for staging and
prognosis reaching optimal performance (minimum discrepancy between training & testing).
Figure 2. Comparison between automated and manual segmentations. Delineation of the diseased areas on chest CT in a
COVID-19 patient: First Row: input, AI-segmentation, expert I-segmentation, expert II-segmentation. Second Row: Box-Plot
Comparisons in terms of Dice similarity and Haussdorf between AI-solution, expert I & expert II, & Plot of correlation
between disease extent automatically measured and the average disease extent measured from the 2 manual segmentations.
Disease extent is expressed as the percentage of lung affected by the disease. Third row: statistical measures on comparisons
between AI, expert I, and expert II segmentations.
deep-learning to quantify COVID-19 disease extent on CT but none of them used a multi-centric cohort while providing
comparisons with segmentations done by radiologists18, 19. Disease extent is the only parameter that can be visually estimated
on chest CT to quantify disease severity4, 5, but visual quantification is difficult and usually coarse. Several AI-based tools have
been recently developed to quantify interstitial lung diseases (ILD)20–23, which share common CT features with COVID-19
pneumonia, especially a predominance of ground glass opacities. In this study, we investigated a fully automatic method
(Figure 1) for disease quantification, staging and short-term prognosis. The approach relied on (i) a disease quantification
solution that exploited 2D & 3D convolutional neural networks using an ensemble method, (ii) a biomarker discovery approach
sought to determine the share space of features that are the most informative for staging & prognosis, & (iii) an ensemble
robust supervised classification method to distinguish patients with severe vs non-severe short-term outcome and among severe
patients those intubated and those who did not survive.
Part I: Disease Quantification
In the context of this work, we report a deep learning-based segmentation tool to quantify COVID-19 disease and lung volume.
For this purpose, we used an ensemble network approach inspired by the AtlasNet framework22. We investigated a combination
of 2D slice-based24 and 3D patch-based ensemble architectures25. The development of the deep learning-based segmentation
solution was done on the basis of a multi-centric cohort of 478 unenhanced chest CT scans (208,668 slices) of COVID-19
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Figure 3. Spider-chart distribution of features depicting their minimum and maximum values [mean value (blue), 70%
percentile (yellow) and 90% percentile (red) lines] with respect to the different outcomes with the following order: top:
non-severe, bottom left: intensive care support & bottom right: deceased in the testing set. White and red circles represent
respectively 40% and 60% of the maximum value of each feature. Clear separation was observed on these feature space with
respect to the non-severe & severe cases. In terms of deceased versus intensive care patients, notable difference were observed
with respect to three variables, the age of the patient, the condition of the healthy lung and the non-uniformity of the disease
(indicated with gray in the spider-chart).
patients with positive RT-PCR. The multicentric dataset was acquired at 6 Hospitals, equipped with 4 different CT models
from 3 different 91 manufacturers, with different acquisition protocols and radiation dose (Table 1). Fifty CT exams from 3
centers were used for training and 130 CT exams from 3 other centers were used for test (Table 2). Disease and lung were
delineated on all 23,423 images used as training dataset, and on only 20 images per exam but by 2 independent annotators in
the test dataset (2,600 images). The overall annotation effort took approximately 800 hours and involved 15 radiologists with 1
to 7 years of experience in chest imaging. The consensus between manual (2 annotators) and automated segmentation was
measured using the Dice similarity score (DSC)26 and the Haussdorf distance (HD). The CovidENet performed equally well to
trained radiologists in terms of DSCs and better in terms HD (Figure 2). The mean/median DSCs between the two expert’s
annotations on the test dataset were 0.70/0.72 for disease segmentation. For the same task, DSCs between CovidENet and the
manual segmentations were 0.69/0.71 and 0.70/0.73. In terms of HDs, the observed average value between the two experts
was 9.16mm while it was 8.96mm between CovidENet and the two experts. When looking at disease extent, defined as the
percentage of lung affected by the disease, we found no significant difference between automated segmentation and the average
of the two manual segmentations (19.9% ±17.7 [0.5−73.2] vs 19.5% ±16.5 [1.1−75.7]; p= 0.352).
Part II: Imaging Biomarker Discovery
To assess the prognostic value of the Chest computed tomography (CT) an extended multi-centric data set was built. We
reviewed outcomes in patient charts within the 4 days following chest CT and divided the patients in 3 groups: those who
didn’t survive, those who required mechanical ventilation and those who were still alive and not intubated. Out of the 478
included patients, 27 died (6%) and 83 were intubated (17%), forming a group of 110 patients with severe short-term outcome
(23%). Data of 383 patients from 3 centers were used for training and those of 85 patients from 3 other centers composed
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Figure 4. Classification performance of dual & aggregated classifiers with respect to the non-severe vs severe case, the
intubated vs deceased case and the three classes. Sensitivity and confusion tables are presented with respect to the different
classification problems.
an independent test dataset (Table 3). Radiomics-based prognosis gained significant attention in the recent years towards
predicting treatment outcomes27. In this study we have adopted a similar strategy, we extracted 107 features related to first
order, higher order statistics, texture and shape information for lungs, disease extent and heart. Feature selection was performed
on a basis of predictive value consensus. We created several representative partitions 117 of the training set (80% training and
20% validation) and run 13 different supervised classification methods towards optimal separation of the observed clinical
ground truth between severe and non-severe cases (Table 4). The features that were shared between the different classifiers
were retained as robust imaging biomarkers using a cut-off probability of 0.25 and were aggregated to patients’ age and gender
(Table 5). In total 12 features were retained for the prognosis part and included age, gender, disease extent, descriptors of
disease heterogeneity and extension, features of healthy lung and a descriptor of cardiac heterogeneity. Correlations for some
these features and the clinical outcome are presented in Figure 5 while a representation of these feature space with respect to
the different classes is presented in Figure 3.
Part III: Staging and Prognosis
The staging/prognosis was implemented using a hierarchical classification principle, targeting first staging and subsequently
prognosis. The staging component sought to separate patients with severe and non-severe short-term outcomes, while the
prognosis sought to predict the risk of decease among severe patients. On the basis of the feature selection step, the machine
learning algorithms that had a balanced accuracy greater than 60% on validation were considered. The selection of these
methods was done on the basis of minimum discrepancy between performance on training and internal validation sub-training
data set. We have built two sequential classifiers using this ensemble method, one to determine the severe cases and a second to
predict survival. The classifier aiming to separate patients with severe and non-severe short-term outcomes had a balanced
accuracy of 74%, a weighted precision of 79%, a weighted sensitivity of 69% and specificity of 79% to predict a severe
short-term outcome (Figure 4, Table 6). The performance of the second classifier aiming to differentiate between intubated and
deceased patients was even higher with a balanced accuracy of 81% (Figure 4, Table 7). The hierarchical classifiers combing
the 3 classes had a balanced accuracy of 68%, a weighted precision of 79%, a weighted sensitivity of 67% and specificity
of 83% (Figure 4). It was observed that prognosis performance difference between training and external cohort testing was
low, suggesting that the most important information present at CT scans was recovered, and additional information should be
integrated in order to fully explain the outcome.
Part IV: Conclusions
In conclusion, artificial intelligence enhanced the value of chest CT by providing fast accurate, and precise disease extent
quantification and by helping to identify patients with severe short-term outcomes. This could be of great help in the current
context of the pandemic with healthcare resources under extreme pressure. In a context where the sensitivity of RT-PCR has
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Figure 5. Discovery of – imaging-biomarkers through consensus. Generic variables (G: age, sex), disease related variables (D:
extent, volume, maximum diameter, etc.), lung variables (L: skewness, etc.) as well as heart related variables (H:
non-uniformity) have been automatically selected. The prevalence of the features as well as their distribution with respect to the
different classes is presented for some of them, with rather clear separation and strong correlations with ground truth.
been shown to be low, such as 63% when perform on nasal swab28, chest CT has been shown to provide higher sensitivity for
diagnosis of COVID-19 as compared with initial RT-PCR from pharyngeal swab samples10. The current COVID-19 pandemic
requires implementation of rapid clinical triage in healthcare facilities to categorize patients into different urgency categories29,
often occurring in the context of limited access to biological tests. Beyond the diagnostic value of CT for COVID-19, our study
suggests that AI should be part of the triage process. The developed tool will be made publicly available. Our prognosis and
staging method achieved state of the art results through the deployment of a highly robust ensemble classification strategy
with automatic feature selection of imaging biomarkers and patients’ characteristics available within the image’ metadata. In
terms of future work, the continuous enrichment of the data base with new examples is a necessary action on top of updating
the outcome of patients included in the study. The integration of non-imaging data and other related clinical and categorical
variables such as lymphopenia, the D-dimer level and other comorbidities9, 30–32 is a necessity towards better understanding the
disease and predicting the outcomes. This is clearly demonstrated from the inability of any of the state-of-the art classification
methods (including neural networks and multi-layer perceptron models) to predict the outcome with a balanced accuracy greater
to 80% on the training data. Our findings could have a strong impact in terms of (i) patient stratification with respect to the
different therapeutic strategies, (ii) accelerated drug development through rapid, reproducible and quantified assessment of
treatment response through the different mid/end-points of the trial, and (iii) continuous monitoring of patient’s response to
treatment.
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Methods
Study Design and Participants
This retrospective multi-center study was approved by our Institutional Review Board (AAA-2020-08007) which waived the
need for patients’ consent. Patients diagnosed with COVID-19 from March 4th to 29th at six large University Hospitals were
eligible if they had positive PCR-RT and signs of COVID-19 pneumonia on unenhanced chest CT. A total of 478 patients
formed the full dataset (208,668 CT slices). Only one CT examination was included for each patient. Exclusion criteria were
(i) contrast medium injection and (ii) important motion artifacts.
For the COVID-19 radiological pattern segmentation part, 50 patients from 3 centers (A: 20 patients; B: 15 patients, C:
15 patients) were included to compose a training and validation dataset, 130 patients from the remaining 3 centers (D: 50
patients; E: 50 patients, F: 30 patients) were included to compose the test dataset (Table 2). The proportion between the CT
manufacturers in the datasets was pre-determined in order to maximize the model generalizability while taking into account the
data distribution.
For the radiomics driven prognosis study, 298 additional patients from centers A (96 patients), B (64 patients) and D (138
patients) were included to increase the size of the dataset. Data of 383 patients from 3 centers (A, B and D) were used for
training and those of 85 patients from 3 other centers (C, E, F) composed an independent test set (Table 3). Only one CT
examination was included for each patient. Exclusion criteria were (i) contrast medium injection and (ii) important motion
artifacts. For short-term outcome assessment, patients were divided into 2 groups: those who died or were intubated in the 4
days following the CT scan composed the severe short-term outcome subgroup, while the others composed the non-severe
short-term outcome subgroup.
CT Acquisitions
Chest CT exams were acquired on 4 different CT models from 3 manufacturers (Aquilion Prime from Canon Medical Systems,
Otawara, Japan; Revolution HD from GE Healthcare, Milwaukee, WI; Somatom Edge and Somatom AS+ from Siemens
Healthineer, Erlangen, Germany). The different acquisition and reconstruction parameters are summarized in Table 1. CT
exams were mostly acquired at 120 (n=103/180; 57%) and 100 kVp (n=76/180; 42%). Images were reconstructed using
iterative reconstruction with a 512×512 matrix and a slice thickness of 0.625 or 1 mm depending on the CT equipment. Only
the lung images reconstructed with high frequency kernels were used for analysis. For each CT examination, dose length
product (DLP) and volume Computed Tomography Dose Index (CTDIvol) were collected.
Data Annotation
Fifteen radiologists (GC, TNHT, SD, EG, NH, SEH, FB, SN, CH, IS, HK, SB, AC, GF and MB) with 1 to 7 years of experience
in chest imaging participated in the data annotation which was conducted over a 2-week period. For the training and validation
set for the COVID-19 radiological pattern segmentation, the whole CT examinations were manually annotated slice by slice
using the open source software ITKsnap 1. On each of the 23,423 axial slices composing this dataset, all the COVID-19
related CT abnormalities (ground glass opacities, band consolidations, and reticulations) were segmented as a single class.
Additionally, the whole lung was segmented to create another class (lung). To facilitate the collection of the ground truth for the
lung anatomy, a preliminary lung segmentation was performed with Myrian XP-Lung software (version 1.19.1, Intrasense,
Montpellier, France) and then manually corrected.
As far as test cohort for the segmentation is concerned, 20 CT slices equally spaced from the superior border of aortic arch
to the lowest diaphragmatic dome were selected to compose a 2,600 images dataset. Each of these images were systematically
annotated by 2 out of the 15 participating radiologists who independently performed the annotation. Annotation consisted of
manual delineation of the disease and manual segmentation of the lung without using any preliminary lung segmentation.
Deep Learning Construction
The segmentation tool was built under the paradigm of ensemble methods using a 2D fully convolutional network together with
the AtlasNet framework22 and a 3D fully convolutional network25. The AtlasNet framework combines a registration stage of
the CT scans to a number of anatomical templates and consequently utilizes multiple deep learning-based classifiers trained for
each template. At the end, the prediction of each model is - to the original anatomy and a majority voting scheme is used to
produce the final projection, combining the results of the different networks. A major advantage of the AtlasNet framework is
that it incorporates a natural data augmentation by registering each CT scan to several templates. Moreover, the framework
is agnostic to the segmentation model that will be utilized. For the registration of the CT scans to the templates, an elastic
registration framework based on Markov Random Fields was used, providing the optimal displacements for each template33.
The architecture of the implemented segmentation models was based on already established fully convolutional neural
network designs from the literature24, 25. Fully convolutional networks following an encoder decoder architecture both in 2D
1http://www.itksnap.org
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and 3D were developed and evaluated. For the 2D models the CT scans were separated on the axial view. The network included
5 convolutional blocks, each one containing two Conv-BN-ReLU layer successions. Maxpooling layers were also distributed
at the end of each convolutional block for the encoding part. Transposed convolutions were used on the decoding part to
restore the spatial resolution of the slices together with the same successions of layers. For the 3D pipeline, the model similarly
consisted of five blocks with a down-sampling operation applied every two consequent Conv3D-BN-ReLU layers. Additionally,
five decoding blocks were utilized for the decoding path, at each block a transpose convolution was performed in order to
up-sample the input. Skip connections were also employed between the encoding and decoding paths. In order to train this
model, cubic patches of size 64×64×64 were randomly extracted within a close range of the ground truth annotation border
in a random fashion. Corresponding cubic patches were also extracted from the ground truth annotation masks and the lung
anatomy segmentation masks. To this end, we trained the model with the CT scan patch as input, the annotation patch as target
and the lung anatomy annotation patch as a mask for calculating the loss function only within the lung region. In order to train
all the models, each CT scan was normalized by cropping the Hounsfield units in the range [−1024, 1000].
Regarding implementation details, 6 templates were used for the AtlasNet framework together with normalized cross
correlation and mutual information as similarities metrics. The networks were trained using weighted cross entropy loss using
weights depending on the appearance of each class and dice loss. Moreover, the 3D network was trained using a dice loss. The
Dice loss (DL) and weighted cross entropy (WCE) are defined as follows,
DL = 1− 2pg+1
p+g+1
, WCE =−(βg log(p)+(1−g)log(1− p))
where p is the predicted from the network value and g the target/ ground truth value. β is the weight given for the less
representative class. For network optimization, we used only the class for the diseased regions.
For the 2D experiments we used classic stochastic gradient descent for the optimization with initial learning rate = 0.01,
decrease of learning rate = 2.5 ·10−3 every 10 epochs, momentum =0.9 and weight decay =5 ·10−4. For the 3D experiments we
used the AMSGrad and a learning rate of 0.001. The training of a single network for both 2D and 3D network was completed in
approximately 12 hours using a GeForce GTX 1080 GPU, while the prediction for a single CT scan was done in a few seconds.
Training and validation curves for one template of AtlasNet and the 3D network are shown in Figure 6. Both Dice similarity
score and Haussdorff distances were higher with the 2D approach compared to the 3D approach (Figure ??). However, the
combination of their probability scores led to a significant improvement. Thus, the ensemble of 2D and 3D architectures was
selected for the final COVID-19 segmentation tool.
Moreover, segmentation masks of the lung and heart of all patients were extracted by using ART-Plan software (Thera-
Panacea, Paris, France). ART-Plan is a CE-marked solution for automatic annotation of organs, harnessing a combination of
anatomically preserving and deep learning concepts. This software has been trained using a combination of a transformation
and an image loss. The transformation loss penalizes the normalized error between the prediction of the network and the affine
registration parameters depicting the registration between the source volume and the whole body scanned. These parameters are
determined automatically using a downhill simplex optimization approach. The second loss function of the network involved an
image similarity function – the zero-normalized cross correlation loss – that seeks to create an optimal visual correspondence
between the observed CT values of the source volume and the corresponding ones at the full body CT reference volume. This
network was trained using as input a combination of 360,000 pairs of CT scans of all anatomies and full body CT scans. These
projections used to determine the organs being present on the test volume. Using the transformation between the test volume
and the full body CT, we were able to determine a surrounding patch for each organ being present in the volume. These patches
were used to train the deep learning model for each full body CT. The next step consisted of creating multiple annotations on
the different reference spaces, and for that a 3D fully convolutional architecture was trained for every reference anatomy. This
architecture takes as input the annotations for each organ once mapped to the reference anatomy and then seeks to determine
for each anatomy a network that can optimally segment the organ of interest similar to the AtlasNet framework used for the
disease segmentation. This information was applied for every organ of interest presented in the input CT Scan. In average,
6,600 samples were used for training per organ after data augmentation. These networks were trained using a conventional dice
loss. The final organ segmentation was achieved through a winner takes all approach over an ensemble networks approach. For
each organ, and for each full body reference CT a specific network was built, and the segmentation masks generated for each
network were mapped back to the original space. The consensus of the recommendations of the different subnetworks was used
to determine the optimal label at the voxel level.
Staging / Prognosis
As a preprocessing step, all images were resampled by cubic interpolation to obtain isometric voxels with sizes of 1 mm.
Subsequently, disease, lung and heart masks were used to extract 107 radiomic features34 for each of them (left and right lung
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were considered separately both for the disease extent and entire lung). The features included first order statistics, shape-based
features in 2D and 3D together with texture-based features. Radiomics features were enriched with clinical data available from
the image metadata (age, gender), disease extent and number of diseased regions. The minimum and maximum values were
calculated for the training and validation cohorts and Min-Max normalization was used to normalize the features, the same
values were also applied on the test set. As a first step, a number of features were selected using a lasso linear model in order to
decrease the dimensionality. The lasso estimator seeks to optimize the following objective function:
||y−Xw||22
2n
+α||w||1
where α is a constant, ||w||1 is the L1-norm of the coefficient vector and n is the number of samples. The Lasso method
was used with 200 alphas along a regularization path of length 0.01 and limited to 1000 iterations. The staging/prognosis
component was addressed using an ensemble learning approach. First, the training data set was subdivided into training and
validation set on the principle of 80%− 20% while respecting that the distribution of classes between the two subsets was
identical to the observed one. We have created 10 subdivisions on this basis and evaluated the average performance of the
following supervised classification methods: Nearest Neighbor, {Linear, Sigmoid, Radial Basis Function, Polynomial Kernel}
Support Vector Machines, Gaussian Process, Decision Trees, Random Forests, AdaBoost, Gaussian Naive Bayes, Bernoulli
Naive Bayes, Multi-Layer Perceptron & Quadratic Discriminant Analysis. Features selection was performed on the training set
of each subdivision. In particular, the features selected in at least three subdivision were considered critical and have been used
later for the staging and prognosis.
• Age
• Gender
• Disease Extent
• From the diseased areas: maximum attenuation, surface, maximum 2D diameter per slice, volume, non-uniformity of the
Gray level Size Zone matrix (GLSZM) and non-uniformity of the Gray level Run Length matrix (GLRLM)
• From the lung areas: skewness and 90th percentile
• From the area of the heart: non-uniformity on the Gray level Size Zone matrix (GLSZM)
These features included first order features (maximum attenuation, skewness and 90th percentile), shape features (surface,
maximum 2D diameter per slice and volume) and texture features (non-uniformity of the GLSZM and GLRLM).
Subsequently, this reduced feature space was considered to be most appropriate for training, and the following 7 classification
methods with acceptable performance, > 60% in terms of balanced accuracy, as well as coherent performance between training
and validation, performance decrease < 20% for the balanced accuracy between training and validation, were trained and
combined together through a winner takes all approach to determine the optimal outcome (Table 4). The final selected methods
include the {Linear, Polynomial Kernel, Radial Basis Function} Support Vector Machines, Decision Trees, Random Forests,
AdaBoost, and Gaussian Naive Bayes which were trained and combined together through a winner takes all approach to
determine the optimal outcome. To overcome the unbalance of the different classes, each class received a weight inversely
proportional to its size. The Support Vector Machines were all three granted a polynomial kernel function of degree 3 and a
penalty parameter of 0.25. In addition, the one with a Radial Basis Function kernel was granted a kernel coefficient of 3. The
decision tree classifier was limited to a depth of 3 to avoid overfitting. The random forest classifier was composed of 8 of such
trees. AdaBoost classifier was based on a decision tree of maximal depth of 2 boosted three times.
The classifiers were applied in a hierarchical way, performing first the staging and then the prognosis. More specifically, a
majority voting method was applied to classify patients into severe and non-severe cases (Table 6). Then, another majority
voting was applied on the cases predicted as severe only to classify them into intubated or deceased (Table 7). In such a setup,
the correlation of the reported features are summarized in Table 5. For the hierarchical prognosis on the three classes a voting
classifier for the prediction of each class against the others has been applied to aggregate the predicted outcomes from the 7
selected methods. In the Figure 8 we visualize the distributions of the different features along the ground truth labels and the
prediction of the hierarchical classifier for each subject. In particular, all the samples are grouped using their ground truth labels
and a boxplot is generated for each group and each feature. Additionally, color coded points are over imposed at each boxplot
denoting the prediction label. It is therefore clearly visible that some features such as the disease extent, the age, the shape of
the disease and the uniformity seems to be very important on separating the different subjects.
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Figure 6. Training and validation curves for one template of AtlasNet and the 3D U-Net.
Statistical Analysis
The statistical analysis for the deep learning-based segmentation framework and the radiomics study was performed using
Python 3.7, Scipy35, Scikit-learn36, TensorFlow37 and Pyradiomics34 libraries. The dice similarity score (DSC)26 was calculated
to assess the similarity between the 2 manual segmentations of each CT exam of the test dataset and between manual and
automated segmentations. The DSC between manual segmentations served as reference to evaluate the similarity between the
automated and the two manual segmentations. Moreover, the Hausdorff distance was also calculated to evaluate the quality of
the automated segmentations in a similar manner. Disease extent was calculated by dividing the volume of diseased lung by the
lung volume and expressed in percentage of the total lung volume. Disease extent measurement between manual segmentations
and between automated and manual segmentations were compared using paired Student’s t-tests.
For the stratification of the dataset into the different categories, classic machine learning metrics, namely balanced accuracy,
weighted precision, and weighted specificity and sensitivity were used. Moreover, the correlations between each feature and the
outcome was computing using a Pearson correlation over the entire dataset.
CT parameters between the 6 centers were compared using the analysis of variance, while patient characteristics between
training/validation and test datasets were compared using chi-square and Student’s t-tests.
Training/ validation dataset Testing dataset
Center A Center B Center C Center D Center E Center F
CT equipment Somatom AS+ Resolution HD Aquilion Prime Somatom Edge Revolution HD Aquilion Prime
Kilovoltage 100-120 120 100-120 100-120 120-140 100-120
DLP
(mGy.cm)
109±42
[44-256]
306±104
[123-648]
102±30
[43-189]
131±44
[55-499]
177±48
[43-276]
115±26
[75 - 186]
CTDIvol
(mGy)
3.2±1.5
[1.2-11.9]
8.7±2.8
[3.9-18.5]
2.7±0.9
[1.0-5.3]
3.2±0.9
[1.4-9.5]
5.5±1.8
[1.2-12.3]
2.5±0.6
[1.7-4.3]
Slice thick-
ness
1mm 0.625mm 1mm 0.625mm 1mm 1mm
Convolution
Kernel
i70 Lung FC51-FC52 i50 Lung FC51-FC52
Iterative re-
constructions
SAFIRE 3 ASIR-v 80% IDR 3D0.67 SAFIRE 4 ASIR-v 60% IDR 3D
Table 1. Acquisition and reconstruction parameters. Note.— For quantitative variables, data are mean ± standard deviation,
and numbers in brackets are the range. CT = Computed Tomography ; CTDIvol = volume Computed Tomography Dose Index ;
DLP = Dose Length Product * significant difference with p < 0.001
References
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Training/Validation Dataset
(Centers A+B+C; N=50)
Test Dataset
(Centers D+E+F; n=130) p value
Age (y) 57±17 [26-97] 59±16 [17-95] 0.363
No. of Men 31(62) 87(67) 0.534
Disease extent*
Manual 18.1± 14.9 [0.3-68.5] 19.5±16.5 [1.1-75.7] 0.574
Automated - 19.9%±17.7 [0.5-73.2] -
DLP (mGy.cm) 180±124 [43-527] 139±49.0 [43-276] 0.026
CTDIvol (mGy) 4.9±3.4 [1.0-13.0] 4.0±1.9 [1.2-12.3] 0.064
Table 2. Patient characteristics in the datasets used for developing the segmentation tool. Note. For quantitative variables,
data are mean ± standard deviation, and numbers in brackets are the range. For qualitative variables, data are numbers of
patients, and numbers in parentheses are percentages. CTDIvol = volume Computed Tomography Dose Index; DLP = Dose
Length Product *Percentage of lung volume on CT, calculated on the full volume for the training/validation dataset and 20
slices in the test dataset
Training/Validation Dataset
(Centers A+B+D*; N=383)
Test Dataset
(Centers C+E+F; n=95) p value
Age (y) 63±16 [24-98] 57±15 [17-97] 0.001
No. of Men 255(67) 65(68) 0.732
Disease extent** 19.6±17.0 [0.0-85.1] 22.5±16.4 [1.1-64.7] 0.126
Short-term outcome
Deceased 19(5) 8(8)
Intubated 65(17) 18(19)
Alive and Not Intubated 299(78) 69(73)
DLP (mGy.cm) 160±97 [44-648] 146±52.0 [ 43-276 ] 0.047
CTDIvol (mGy) 4.3±2.8 [1.2-18.5] 4.1±2.0 [1.0-12.3] 0.064
Table 3. Patient characteristics in the dataset used for the developed prognosis model using radiomics. Note.— For
quantitative variables, data are mean ± standard deviation, and numbers in brackets are the range. For qualitative variables,
data are numbers of patients, and numbers in parentheses are percentages. CTDIvol = volume Computed Tomography Dose
Index; DLP = Dose Length Product, ∗Enlarged by including all eligible patients over the study period, ∗∗Percentage of lung
volume on the whole CT
2. Bai, H. X. et al. Performance of radiologists in differentiating covid-19 from viral pneumonia on chest ct. Radiology
200823 (2020).
3. Bernheim, A. et al. Chest ct findings in coronavirus disease-19 (covid-19): relationship to duration of infection. Radiology
200463 (2020).
4. Li, K. et al. Ct image visual quantitative evaluation and clinical classification of coronavirus disease (covid-19). Eur.
Radiol. 1–10 (2020).
5. Yuan, M., Yin, W., Tao, Z., Tan, W. & Hu, Y. Association of radiologic findings with mortality of patients infected with
2019 novel coronavirus in wuhan, china. PLoS One 15, e0230548 (2020).
6. Truog, R. D., Mitchell, C. & Daley, G. Q. The toughest triage—allocating ventilators in a pandemic. New Engl. J. Medicine
(2020).
7. White, D. B. & Lo, B. A framework for rationing ventilators and critical care beds during the covid-19 pandemic. Jama
(2020).
8. Zhu, N. et al. A novel coronavirus from patients with pneumonia in china, 2019. New Engl. J. Medicine (2020).
9. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: a retrospective
cohort study. The Lancet (2020).
10. Ai, T. et al. Correlation of chest ct and rt-pcr testing in coronavirus disease 2019 (covid-19) in china: a report of 1014
cases. Radiology 200642 (2020).
11. Fang, Y. et al. Sensitivity of chest ct for covid-19: comparison to rt-pcr. Radiology 200432 (2020).
11/16
Classifier
Balanced Accuracy Weighted Precision Weighted Sensitivity Weighted Specificity
Training Validation Training Validation Training Validation Training Validation
Nearest
Neighbors
0.66
±0.02
0.55
±0.03
0.88
±0.01
0.73
±0.03
0.85
±0.01
0.78
±0.01
0.47
±0.03
0.32
±0.04
L-SVM* 0.71±0.02
0.67
±0.04
0.80
±0.02
0.77
±0.03
0.68
±0.02
0.67
±0.04
0.74
±0.03
0.67
±0.06
P-SVM* 0.77±0.02
0.66
±0.04
0.83
±0.01
0.76
±0.03
0.77
±0.03
0.72
±0.03
0.76
±0.03
0.61
±0.07
S-SVM
0.53
±0.02
0.55
±0.05
0.69
±0.04
0.69
±0.04
0.49
±0.08
0.51
±0.1
0.57
±0.09
0.58
±0.11
RBF-SVM* 0.74±0.02
0.67
±0.06
0.82
±0.01
0.77
±0.04
0.66
±0.02
0.63
±0.06
0.81
±0.02
0.71
±0.08
Gaussian
Process
0.63
±0.03
0.59
±0.04
0.82
±0.02
0.77
±0.04
0.83
±0.01
0.80
±0.02
0.43
±0.04
0.38
±0.05
Decision
Tree*
0.78
±0.02
0.68
±0.04
0.85
±0.01
0.78
±0.03
0.69
±0.03
0.64
±0.05
0.87
±0.03
0.72
±0.08
Random
Forest*
0.78
±0.02
0.64
±0.06
0.84
±0.02
0.75
±0.04
0.74
±0.03
0.65
±0.07
0.82
±0.04
0.63
±0.09
Multi-Layer
Perceptron
0.83
±0.04
0.58
±0.03
0.90
±0.02
0.72
±0.02
0.9
±0.02
0.73
±0.03
0.77
±0.06
0.43
±0.05
AdaBoost* 0.8±0.03
0.63
±0.03
0.86
±0.01
0.75
±0.03
0.76
±0.07
0.66
±0.07
0.83
±0.08
0.6
±0.11
Gaussian
Naive Bayes*
0.66
±0.02
0.63
±0.05
0.76
±0.01
0.74
±0.03
0.74
±0.01
0.72
±0.04
0.57
±0.03
0.53
±0.07
Bernouilli
Naive Bayes
0.51
±0.01
0.50
±0.01
0.74
±0.05
0.63
±0.05
0.78
±0.0
0.77
±0.01
0.24
±0.01
0.22
±0.02
QDA
0.72
±0.01
0.60
±0.04
0.82
±0.01
0.73
±0.03
0.82
±0.01
0.75
±0.03
0.62
±0.02
0.45
±0.07
Table 4. Performances of the 13 evaluated classifiers. Note.— Asterixis indicates the 7 classifiers reporting a balanced
accuracy higher than 0.60 and that were finally selected, L-SVM = Support Vector Machine with a linear kernel; L-SVM =
Support Vector Machine with a polynomial kernel, L-SVM = Support Vector Machine with a sigmoid kernel, RBF-SVM =
Support Vector Machine with a Radial Basis Function, QDA = Quadratic Discriminant Analysis
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Eur. J. Radiol. 123, 108774 (2020).
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15. Ardila, D. et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed
tomography. Nat. medicine 25, 954–961 (2019).
16. Wang, L. & Wong, A. Covid-net: A tailored deep convolutional neural network design for detection of covid-19 cases
from chest radiography images. arXiv preprint arXiv:2003.09871 (2020).
17. Li, L. et al. Artificial intelligence distinguishes covid-19 from community acquired pneumonia on chest ct. Radiology
200905 (2020).
18. Chaganti, S. et al. Quantification of tomographic patterns associated with covid-19 from chest ct. arXiv preprint
arXiv:2004.01279 (2020).
19. Huang, L. et al. Serial quantitative chest ct assessment of covid-19: Deep-learning approach. Radiol. Cardiothorac.
Imaging 2, e200075 (2020).
20. Jacob, J. et al. Mortality prediction in ipf: evaluation of automated computer tomographic analysis with conventional
severity measures. Eur. Respir. J. ERJ–01011 (2016).
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Features CorrelationSevere vs Non Severe Intubated vs Diseased Hierarchical Classifier
Age -0.0681 0.6745 0.1853
Gender -0.1517 0.0211 0.1443
Disease Extent -0.3809 -0.0280 0.3491
Heart
non-uniformity
on the GLSZM -0.1953 -0.0935 0.1537
Left Right Left Right Left Right
Lung Skewness 0.3324 0.3675 0.1018 -0.0229 -0.2967 -0.344790th Percentile -0.2808 -0.3221 -0.0576 0.0035 0.2526 0.3119
Disease
Maximum
attenuation -0.0867 -0.1978 0.0885 0.0035 0.0958 0.1846
Surface -0.3382 -0.3289 -0.0174 0.0381 0.3034 0.3112
Maximum 2D
diameter per
slice
-0.2304 -0.2236 0.1238 0.1010 0.2288 0.2183
Volume -0.3592 -0.3971 -0.0489 0.0840 0.3241 0.3863
Non-uniformity
on the GLSZM
-0.2944 -0.3448 -0.1379 -0.0805 0.2375 0.3004
Non-uniformity
on the GLRLM -0.3280 -0.3372 -0.0219 0.0829 0.3000 0.3319
Table 5. Correlation between outcome and the 12 selected features. Note.—Note.— GLSZM =Gray level Size Zone matrix ,
GLRLM = Gray level Run Length matrix
22. Vakalopoulou, M. et al. Atlasnet: Multi-atlas non-linear deep networks for medical image segmentation. In Frangi, A. F.,
Schnabel, J. A., Davatzikos, C., Alberola-López, C. & Fichtinger, G. (eds.) Medical Image Computing and Computer
Assisted Intervention – MICCAI 2018, 658–666 (Springer International Publishing, Cham, 2018).
23. Anthimopoulos, M. et al. Semantic segmentation of pathological lung tissue with dilated fully convolutional networks.
IEEE journal biomedical health informatics 23, 714–722 (2018).
24. Badrinarayanan, V., Kendall, A. & Cipolla, R. Segnet: A deep convolutional encoder-decoder architecture for image
segmentation. IEEE transactions on pattern analysis machine intelligence 39, 2481–2495 (2017).
25. Çiçek, Ö., Abdulkadir, A., Lienkamp, S. S., Brox, T. & Ronneberger, O. 3d u-net: learning dense volumetric segmentation
from sparse annotation. In International conference on medical image computing and computer-assisted intervention,
Classifier
Balanced
Accuracy
Weighted
Precision
Weighted
Sensitivity
Weighted
Specificity
Training Test Training Test Training Test Training Test
L-SVM 0.71 0.7 0.8 0.76 0.68 0.67 0.75 0.73
P-SVM 0.76 0.67 0.82 0.73 0.75 0.69 0.76 0.65
RBF-SVM 0.72 0.71 0.81 0.79 0.65 0.63 0.79 0.79
Decision Tree 0.76 0.65 0.85 0.74 0.65 0.56 0.88 0.74
Random Forest 0.76 0.7 0.82 0.76 0.71 0.65 0.8 0.75
AdaBoost 0.77 0.67 0.83 0.74 0.71 0.62 0.82 0.71
Gaussian
Naive Bayes 0.65 0.73 0.76 0.77 0.73 0.76 0.57 0.69
Ensemble
Classifier 0.75 0.74 0.82 0.79 0.69 0.69 0.81 0.79
Table 6. Performances of each of the 7 individual classifiers and of the ensemble classifier to differentiate between patient
with severe and non-severe short-term outcome. Note.— L-SVM = Support Vector Machine with a linear kernel; L-SVM =
Support Vector Machine with a polynomial kernel, RBF-SVM = Support Vector Machine with a Radial Basis Function kernel
13/16
Classifier
Balanced
Accuracy
Weighted
Precision
Weighted
Sensitivity
Weighted
Specificity
Training Test Training Test Training Test Training Test
L-SVM 0.84 0.78 0.87 0.84 0.81 0.85 0.87 0.72
P-SVM 0.95 0.81 0.96 0.9 0.95 0.88 0.95 0.74
RBF-SVM 0.9 0.62 0.92 0.83 0.90 0.77 0.9 0.48
Decision Tree 0.97 0.75 0.98 0.87 0.98 0.85 0.96 0.65
Random Forest 0.94 0.75 0.96 0.87 0.96 0.85 0.92 0.65
AdaBoost 1 0.62 1 0.83 1 0.77 1 0.48
Gaussian
Naive Bayes 0.82 0.75 0.86 0.87 0.83 0.85 0.8 0.65
Ensemble
Classifier 0.96 0.81 0.97 0.9 0.96 0.88 0.95 0.74
Table 7. Performances of each of the 7 individual classifiers and of the ensemble classifier to differentiate between intubated
and deceased patients. Note.— L-SVM = Support Vector Machine with a linear kernel; L-SVM = Support Vector Machine with
a polynomial kernel, RBF-SVM = Support Vector Machine with a Radial Basis Function kernel
424–432 (Springer, 2016).
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27. Sun, R. et al. A radiomics approach to assess tumour-infiltrating cd8 cells and response to anti-pd-1 or anti-pd-l1
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Figure 7. Some additional qualitative analysis for the comparison between automated and manual segmentations. Delineation
of the diseased areas on chest CT in different slices of COVID-19 patients: From left to right: Input, AI-segmentation, expert
I-segmentation, expert II-segmentation
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Figure 8. Boxplots of the selected features and their association with the predicted outcomes and ground truth labels.
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